Business Context and Reporting Period
This Form 8-K, filed on May 5, 2011, by Accuray Incorporated, reports financial results for the third quarter of fiscal 2011 ended March 31, 2011. The filing also addresses the pending acquisition of TomoTherapy, which significantly impacted the quarter's financial performance.
Key Financial Metrics
| Metric | Q3 2011 | Q3 2010 | 9 Months 2011 | 9 Months 2010 |
|---|---|---|---|---|
| Total Net Revenue | $54.7 million | $51.9 million | $147.1 million | $159.8 million |
| Gross Profit | $27.3 million | $25.4 million | $75.0 million | $73.0 million |
| Operating Income (Loss) | $(0.5) million | $2.8 million | $(3.0) million | $(3.2) million |
| Net Income (Loss) | $(1.2) million | $2.3 million | $(1.7) million | $(2.2) million |
| Diluted EPS | $(0.02) | $0.04 | $(0.03) | $(0.04) |
| Cash and Equivalents | $57.3 million | N/A | N/A | N/A |
| Total Backlog | $413.4 million | N/A | N/A | N/A |
Liquidity and Debt: As of March 31, 2011, Accuray held $57.3 million in cash and cash equivalents and $85.6 million in short-term available-for-sale securities. The filing does not disclose specific long-term debt figures, though total liabilities were $82.5 million.
Material Changes vs. Prior Period
- Profitability Reversal: The company reported a net loss of $1.2 million in Q3 2011, a significant shift from the net income of $2.3 million in Q3 2010. This reversal was primarily driven by approximately $2.6 million in costs associated with the pending acquisition of TomoTherapy.
- Revenue Growth: Total revenue increased 5% year-over-year to $54.7 million. However, revenue from shared ownership programs and other categories showed mixed performance, with product revenue rising slightly while service revenue remained relatively flat.
- Backlog Expansion: Total backlog increased 18% year-over-year to $413.4 million, driven by $58.5 million in new orders during the quarter. System backlog rose 27% year-over-year, while service backlog increased 18%.
- Installed Base: The worldwide CyberKnife installed base grew to 226 systems following the shipment of 13 units and installation of 4 units in the quarter.
Outlook, Risks, and Unusual Items
- Acquisition Costs: The $2.6 million in transaction costs related to the TomoTherapy acquisition is an unusual item that materially affected the bottom line for the quarter.
- Forward-Looking Risks: Management highlighted significant risks regarding the TomoTherapy transaction, including the satisfaction of closing conditions, market conditions, and the potential inability to successfully integrate the businesses.
- Order Volatility: While 13 new CyberKnife orders were added, two orders were cancelled by customers, and one order aged beyond 2.5 years and was removed from backlog.
- Guidance: The filing does not provide specific numerical guidance for future periods, referring investors to the Form 10-Q and Form S-4 for detailed risk factors.
Investor Verification Checklist
- Verify the status and closing conditions of the pending TomoTherapy acquisition.
- Review the detailed breakdown of the $2.6 million in acquisition-related costs to assess future recurrence.
- Monitor the conversion rate of the $413.4 million backlog into revenue, noting the impact of order cancellations and aging.
- Assess the impact of the reduced deferred revenue recognition from legacy Platinum service agreements ($0.2 million vs. $2.1 million prior year).
- Confirm the company's liquidity position relative to operating expenses and potential integration costs.